Picture of Alaunos Therapeutics logo

TCRT Alaunos Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m+98.11%
3m+219.43%
6m+166.78%
1yr-36.97%
Volume Change (%)
10d/3m-79.01%
Price vs... (%)
52w High-26.74%
50d MA+70.5%
200d MA+120.45%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)13.88
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value9.59
Price to Tang. Book9.59
Price to Free Cashflown/a
Price to Sales1,014.84
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-393.48%
Return on Equity-139.06%
Operating Margin-41630%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Alaunos Therapeutics EPS forecast chart

Profile Summary

Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.

Directors

Last Annual
December 31st, 2024
Last Interim
March 31st, 2025
Incorporated
May 16th, 2005
Public Since
August 20th, 2004
No. of Shareholders
129
No. of Employees
1
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
1,978,246

TCRT Share Price Performance

Upcoming Events for TCRT

Alaunos Therapeutics Inc Annual Shareholders Meeting

Q2 2025 Alaunos Therapeutics Inc Earnings Release

Q3 2025 Alaunos Therapeutics Inc Earnings Release

Similar to TCRT

Picture of ABVC Biopharma logo

ABVC Biopharma

us flag iconNASDAQ Capital Market

Picture of Acesis Holdings logo

Acesis Holdings

us flag iconNASDAQ Capital Market

Picture of Achieve Life Sciences logo

Achieve Life Sciences

us flag iconNASDAQ Capital Market

Picture of Aclarion logo

Aclarion

us flag iconNASDAQ Capital Market

Picture of Acurx Pharmaceuticals logo

Acurx Pharmaceuticals

us flag iconNASDAQ Capital Market

FAQ